Topics

Clinical Trials About "Xanthine Oxidase Inhibitor nonsteroidal anti inflammatory drug Gout" RSS

22:02 EST 25th January 2020 | BioPortfolio

We list hundreds of Clinical Trials about "Xanthine Oxidase Inhibitor nonsteroidal anti inflammatory drug Gout" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.

More Information about "Xanthine Oxidase Inhibitor nonsteroidal anti inflammatory drug Gout" on BioPortfolio

We have published hundreds of Xanthine Oxidase Inhibitor nonsteroidal anti inflammatory drug Gout news stories on BioPortfolio along with dozens of Xanthine Oxidase Inhibitor nonsteroidal anti inflammatory drug Gout Clinical Trials and PubMed Articles about Xanthine Oxidase Inhibitor nonsteroidal anti inflammatory drug Gout for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Xanthine Oxidase Inhibitor nonsteroidal anti inflammatory drug Gout Companies in our database. You can also find out about relevant Xanthine Oxidase Inhibitor nonsteroidal anti inflammatory drug Gout Drugs and Medications on this site too.

Showing "Xanthine Oxidase Inhibitor nonsteroidal anti inflammatory drug Gout" Clinical Trials 1–25 of 17,000+

Extremely Relevant

A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia

The aim of this 12-week randomized multicenter double-blind double-dummy parallel group placebo and active comparator-controlled dose finding study is to assess the efficacy and safety of four different doses of LC350189 in subjects with hyperuricemia and a diagnosis of gout.


The Effect of Naproxen on the Pharmacokinetic Profile of LC350189 in Healthy Adults

This is a Phase 1, open-label, fixed-sequence, 3-period, 2-way drug interaction study designed to assess the pharmacokinetics, pharmacodynamics, safety, and tolerability of LC350189 and Naproxen when administered alone and in combination in healthy subjects.

Post-Authorisation Safety Study of Lesinurad

Non-interventional population-based prospective cohort study in multiple databases comparing patients with gout who initiate lesinurad in combination with an existing xanthine oxidase inhibitor (XOI) (lesinurad+XOI cohort) to a propensity score-matched cohort of similar patients from the same data source who continue treatment with XOI monotherapy (XOI mono cohort). Study will characterize the cardiovascular safety of lesinurad in combination with XOI in patients with gout aged...


The Effect of Colchicine on the Pharmacokinetic Profile of LC350189 in Healthy Aldults.

This is a Phase 1, open-label, fixed-sequence, 3-period, 2-way drug interaction study designed to assess the PK, PD, safety, and tolerability of LC350189 and colchicine when administered alone and in combination in healthy subjects.

Zurig (Febuxostat) 40mg Efficacy and Safety Trial

Febuxostat is a potent, nonpurine, selective inhibitor of Xanthine oxidase that exhibits antihyperuricemic activity by reducing the formation of uric acid. The investigators conducted an interventional, two-arm, randomized, open label pilot study on patients with serum urate level ≥ 6.8 mg/dL. Patients were treated with Febuxostat 40 mg Tablets or Allopurinol 300 mg Tablets once daily dose for 90 days to determine the efficacy and safety of Febuxostat in comparison with Allop...

Uric Acid Metabolism, Endothelial Function and Oxidative Stress in Vegans and Omnivores.

50 vegans and 50 omnivores will be recruited at the Erasme Hospital, Brussels. Hypothesis - Relative induced-hyperuricemia by the vegan diet is not associated with impaired endothelial function if vitamin B12 and folic acid levels are normal. - Quantification of xanthine oxidoreductase (XOR) isoforms varies according to the diet. Omnivores present more xanthine oxidase (XO) than vegans in which the xanthine dehydrogenase (XD) isoform is more preval...

Role of Allopurinol on Oxidative Stress and Mitochondrial Alterations in Skeletal Muscle of Diabetic Patients

Our recent data in mice have demonstrated a key role of xanthine oxidase in hyperglycemia-induced by Reactive oxygen species production, and a preventive role of allopurinol (inhibitor of xanthine oxidase) on the keeping of mitochondria number and structure, in skeletal muscle of diabetic mice. The investigators want to initiate a clinical trial in order to evaluate the efficacy of allopurinol on the improvement of mitochondrial alterations, oxidative capacities and insulin sen...

Uric Acid and Hypertension in African Americans

This study will test the hypothesis that the administration of a xanthine oxidase inhibitor (allopurinol) will prevent thiazide-induced hyperuricemia, which will result in better blood pressure (BP) control in African Americans.

Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicine

The purpose of this study is to demonstrate that canakinumab given upon acute gout flares relieves the signs and symptoms and prevents recurrence of gout flares in patients with frequent flares of gout for whom NSAIDs and/ or colchicine are contraindicated, not tolerated or ineffective. The efficacy of canakinumab will be compared to the corticosteroid triamcinolone acetonide

A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab (AIN457) to Examine the Clinical Efficacy and the Nonsteroidal Anti-inflammatory Drug (NSAID)-Sparing Effect of Secukinumab Over 16 Weeks in Patients With Ankylosing Spondylit

The current study will assess the clinical Assessment of SpondyloArthritis international Society (ASAS) 20 response to Secukinumab and evaluate to which extent concomitant nonsteroidal anti-inflammatory drug (NSAID) treatment can be reduced in patients treated with Secukinumab or placebo following an initial run-in phase of stable NSAID therapy. In case of a positive outcome concerning the NSAID reduction this study could trigger the development of a guidance concerning NSAID r...

PREventative Study Against URate-Lowering Drug-Induced Gout Exacerbations (PRE-SURGE 2)

The purpose of this clinical research study is to determine the safety and effectiveness of an experimental drug called rilonacept in subjects with gout who are beginning allopurinol treatment for gout. Subjects will participate in this study for approximately 22 weeks. Rilonacept is being studied for use in preventing allopurinol-induced gout flares.

PREventative Study Against URate-lowering Drug-induced Gout Exacerbations 1

The purpose of this clinical research study is to determine the safety and effectiveness of an experimental drug called rilonacept in subjects with gout who are beginning allopurinol treatment for gout. Subjects will participate in this study for approximately 22 weeks. Rilonacept is being studied for use in preventing allopurinol-induced gout flares.

Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicine

The purpose of this extension study is to collect additional safety, tolerability and efficacy data in patients who have completed the core study CACZ885H2357 to support the registration of canakinumab for the indication of gout.

Relevant

Intravenous Allopurinol in Heart Failure

This study tests the hypothesis that allopurinol, a xanthine oxidase inhibitor, improves heart metabolism in patients with heart failure.

Efficacy and Safety Study of HZT-501 in Subjects Requiring Nonsteroidal Anti-Inflammatory Drug (NSAID) Treatment

The purpose of this study is to evaluate whether HZT-501 is effective in reducing the rate of development of ibuprofen-associated ulcers in patients who require long-term daily use of ibuprofen.

Diclofenac Potassium Alone Versus Diclofenac Potassium With Hyoscine-N-butyl Bromide (HBB in Endoscopy

Diclofenac is a proven, commonly prescribed nonsteroidal anti-inflammatory drug (NSAID) that has analgesic, anti-inflammatory, and antipyretic properties, and has been shown to be effective in treating a variety of acute and chronic pain and inflammatory conditions.

Safety and Efficacy of Nonsteroidal Antiinflammatory (NSAI)Drug and Glucocorticoids in Acute Sciatica

The purpose of this study is to determine whether anti-inflammatory drugs or glucocorticoids are effective in the treatment of acute sciatica

Preeclampsia And Nonsteroidal Drugs for Analgesia: a Randomized Non Inferiority Trial

A randomized non-inferiority trial of women with preeclampsia with severe features to determine if the addition of nonsteroidal anti-inflammatory drugs is inferior or non-inferior to standard analgesic bundles in their impact on postpartum hypertension.

Toward Better Outcomes in Osteoarthritis

This study will determine if there is a difference between commonly used nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen (a pain-reliever that does not prevent inflammation) for treating knee pain in osteoarthritis (OA). The two main results we will look at are disease progression according to x-rays and disability over 3.5 years. Study participants with moderate knee OA and knee pain will continue taking their NSAID or stop taking their NSAID and start taking a...

The Drug-Drug Interaction of SHR4640, Febuxostat and Colchicine in Patients With Gout

The objective of the study is to assess the pharmacodynamic properties of drug-drug of SHR4640, Febuxostat and Colchicine interaction in patients with gout.

Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicine

The purpose of this second extension study is to collect long-term safety and tolerability data and additional efficacy data in patients who are treated on demand upon flare with canakinumab.

Targeted Dose Finding of Canakinumab (ACZ885) for Management of Acute Flare in Refractory or Contraindicated Gout Patients

This 8-week study is designed to determine the target dose of canakinumab (ACZ885) for the management of acute flare in gout patients who are contraindicated to Non-Steroidal anti-inflammatory drugs and/or colchicine. The efficacy of ACZ885 will be compared to the corticosteroid triamcinolone acetonide.

Assessing the Role of the NLRP3 Inflammasome in Intercritical Gout

Gout is an autoinflammatory disease characterized by flares of painful joint inflammation. This inflammation occurs in response to uric acid that crystallizes. After a gout attack, patients usually enter a period that is accompanied by low grade inflammation but is otherwise relatively asymptomatic. Gout is typically associated with certain markers, and this study is going describe specific markers in patients that are in between gout attacks. Research has been focused on study...

A Phase Ⅰ Study of PEGylated Recombinant Candida Urate Oxidase (SSS11) in Chinese Healthy Adult Volunteers

To evaluate the safety, tolerability, PK and preliminary PD of SSS11 for injection in chinese healthy adult volunteers.

Study of the Safety and Effectiveness of Rilonacept for the Prevention of Gout Flares

This is a clinical research study to determine the safety and effectiveness of an experimental drug called rilonacept in subjects with gout who are beginning another additional treatment. Subjects will participate in this study for approximately 24 weeks. Rilonacept is being studied for use in preventing gout attacks in patients who have gout.


More From BioPortfolio on "Xanthine Oxidase Inhibitor nonsteroidal anti inflammatory drug Gout"

Quick Search